EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut Microbiota-Mediated Pharmacokinetic Drug–Drug Interactions between Mycophenolic Acid and Trimethoprim-Sulfamethoxazole in Humans

Nahathai Dukaew iD, Patcharawadee Thongkumkoon, Nutnicha Sirikaew, Sivamoke Dissook iD, Wannachai Sakuludomkan, Siripong Tongjai iD, Parameth Thiennimitr iD, Mingkwan Na Takuathung iD, Juthipong Benjanuwattra, Prachya Kongthaweelert, Nut Koonrungsesomboon iD

Pharmaceutics · 14.06.2023 · 15 (6) · 1734

DOI: 10.3390/pharmaceutics15061734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 14.06.2023. Verfasst von Nahathai Dukaew und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Chiang Mai University, 110 Intawaroros Road, Sriphoom, Muang, Chiang Mai 50200, Thailand. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Systems Research Institute, Faculty of Medicine, Chiang Mai University, Faculty of Medicine Research Fund, Chiang Mai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycophenolic acid (MPA) and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed together in certain groups of patients, including solid organ transplant recipients. However, little is known about the pharmacokinetic drug–drug interactions (DDIs) between these two medications. Therefore, the present study aimed to determine the effects of TMP-SMX on MPA pharmacokinetics in humans and to find out the relationship between MPA pharmacokinetics and gut microbiota alteration. This study enrolled 16 healthy volunteers to take a single oral dose of 1000 mg mycophenolate mofetil (MMF), a prodrug of MPA, administered without and with concurrent use of TMP-SMX (320/1600 mg/day) for five days. The pharmacokinetic parameters of MPA and its glucuronide (MPAG) were measured using high-performance liquid chromatography. The composition of gut microbiota in stool samples was profiled using a 16S rRNA metagenomic sequencing technique during pre- and post-TMP-SMX treatment. Relative abundance, bacterial co-occurrence networks, and correlations between bacterial abundance and pharmacokinetic parameters were investigated. The results showed a significant decrease in systemic MPA exposure when TMP-SMX was coadministered with MMF. Analysis of the gut microbiome revealed altered relative abundance of two enriched genera, namely the genus Bacteroides and Faecalibacterium, following TMP-SMX treatment. The relative abundance of the genera Bacteroides, [Eubacterium] coprostanoligenes group, [Eubacterium] eligens group, and Ruminococcus appeared to be significantly correlated with systemic MPA exposure. Coadministration of TMP-SMX with MMF resulted in a reduction in systemic MPA exposure. The pharmacokinetic DDIs between these two drugs were attributed to the effect of TMP-SMX, a broad-spectrum antibiotic, on gut microbiota-mediated MPA metabolism.

Schlagwörter

Stichwörter der Autor:innen

drug–drug interactiongut microbiotamycophenolate mofetilmycophenolic acidpharmacokineticstrimethoprim-sulfamethoxazole

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Chiang Mai University, 110 Intawaroros Road, Sriphoom, Muang, Chiang Mai 50200, Thailand.
  • Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Center for Research and Development of Natural Products for Health, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

ORCID-Profile: Nahathai Dukaew, Sivamoke Dissook, Siripong Tongjai, Parameth Thiennimitr, Mingkwan Na Takuathung, Nut Koonrungsesomboon

Förderung

  • Health Systems Research Institute
  • Faculty of Medicine, Chiang Mai University
  • Faculty of Medicine Research Fund, Chiang Mai University

Zitieren

APA

Dukaew, N., Thongkumkoon, P., Sirikaew, N., Dissook, S., Sakuludomkan, W., Tongjai, S., Thiennimitr, P., Na Takuathung, M., Benjanuwattra, J., Kongthaweelert, P., & Koonrungsesomboon, N. (2023). Gut Microbiota-Mediated Pharmacokinetic Drug–Drug Interactions between Mycophenolic Acid and Trimethoprim-Sulfamethoxazole in Humans. Pharmaceutics, 15(6), 1734. https://doi.org/10.3390/pharmaceutics15061734

Vancouver

Dukaew N, Thongkumkoon P, Sirikaew N, Dissook S, Sakuludomkan W, Tongjai S, et al. Gut Microbiota-Mediated Pharmacokinetic Drug–Drug Interactions between Mycophenolic Acid and Trimethoprim-Sulfamethoxazole in Humans. Pharmaceutics. 2023;15(6):1734. doi:10.3390/pharmaceutics15061734

BibTeX
@article{Dukaew2023,
  author = {Dukaew, Nahathai and Thongkumkoon, Patcharawadee and Sirikaew, Nutnicha and Dissook, Sivamoke and Sakuludomkan, Wannachai and Tongjai, Siripong and Thiennimitr, Parameth and Na Takuathung, Mingkwan and Benjanuwattra, Juthipong and Kongthaweelert, Prachya and Koonrungsesomboon, Nut},
  title = {Gut Microbiota-Mediated Pharmacokinetic Drug–Drug Interactions between Mycophenolic Acid and Trimethoprim-Sulfamethoxazole in Humans},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1734},
  doi = {10.3390/pharmaceutics15061734}
}
Kostenlos starten →